N-(2-hydroxy)-propyl-3-trimethylammonium, o-mysristoyl chitosan enhances the solubility and intestinal permeability of anticancer curcumin

Detalhes bibliográficos
Autor(a) principal: Silva, D
Data de Publicação: 2018
Outros Autores: Santos, D, Almeida, A, Marchiori, L, Campana-Filho, SP, Ribeiro, S, Sarmento, B
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://hdl.handle.net/10216/127428
Resumo: An amphiphilic derivative of chitosan containing quaternary ammonium and myristoyl groups, herein named as ammonium myristoyl chitosan (DMCat), was synthesized by reacting glycidyltrimethylammonium chloride (GTMAC) and myristoyl chitosan (DMCh). The success of the modification was confirmed using Fourier-transform infrared spectroscopy (FTIR) and 1 H nuclear magnetic resonance (NMR) spectroscopy. The average degrees of alkylation and quaternization (DQ) were determined by using 1 H NMR and conductometric titration. The zeta potential of the micelles was higher than 28 mV while its average size and encapsulation efficiency ranged from 280 nm to 375 nm and 68% to 100%, respectively. The in vitro cytotoxicity of the unloaded and curcumin (CUR)-loaded micelles was tested against Caco-2 and HT29-MTX intestinal epithelial cell lines. The results showed no cytotoxic effect from loaded and unloaded micelles as compared to free CUR. In the permeability test, it was observed that both types of micelles, i.e., DMCh and DMCat, improved CUR permeability. Additionally, higher permeability was verified for both systems in Caco-2/HT29-MTX:Raji B because of the mucoadhesive character of chitosan and its ability to open tight junctions. The results indicated that DMCat micelles, due to the physico-chemical, improved characteristics may be a promising carrier to encapsulate CUR aiming cancer therapy.
id RCAP_98bf7c52f82704e6cee8567ab9edd9dc
oai_identifier_str oai:repositorio-aberto.up.pt:10216/127428
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling N-(2-hydroxy)-propyl-3-trimethylammonium, o-mysristoyl chitosan enhances the solubility and intestinal permeability of anticancer curcuminAmphiphilic polymersChitosan derivativesCurcuminIntestinal deliveryPolymeric micellesQuaternizationAn amphiphilic derivative of chitosan containing quaternary ammonium and myristoyl groups, herein named as ammonium myristoyl chitosan (DMCat), was synthesized by reacting glycidyltrimethylammonium chloride (GTMAC) and myristoyl chitosan (DMCh). The success of the modification was confirmed using Fourier-transform infrared spectroscopy (FTIR) and 1 H nuclear magnetic resonance (NMR) spectroscopy. The average degrees of alkylation and quaternization (DQ) were determined by using 1 H NMR and conductometric titration. The zeta potential of the micelles was higher than 28 mV while its average size and encapsulation efficiency ranged from 280 nm to 375 nm and 68% to 100%, respectively. The in vitro cytotoxicity of the unloaded and curcumin (CUR)-loaded micelles was tested against Caco-2 and HT29-MTX intestinal epithelial cell lines. The results showed no cytotoxic effect from loaded and unloaded micelles as compared to free CUR. In the permeability test, it was observed that both types of micelles, i.e., DMCh and DMCat, improved CUR permeability. Additionally, higher permeability was verified for both systems in Caco-2/HT29-MTX:Raji B because of the mucoadhesive character of chitosan and its ability to open tight junctions. The results indicated that DMCat micelles, due to the physico-chemical, improved characteristics may be a promising carrier to encapsulate CUR aiming cancer therapy.MDPI20182018-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10216/127428eng1999-492310.3390/pharmaceutics10040245Silva, DSantos, DAlmeida, AMarchiori, LCampana-Filho, SPRibeiro, SSarmento, Binfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-29T13:00:35Zoai:repositorio-aberto.up.pt:10216/127428Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T23:31:40.234122Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv N-(2-hydroxy)-propyl-3-trimethylammonium, o-mysristoyl chitosan enhances the solubility and intestinal permeability of anticancer curcumin
title N-(2-hydroxy)-propyl-3-trimethylammonium, o-mysristoyl chitosan enhances the solubility and intestinal permeability of anticancer curcumin
spellingShingle N-(2-hydroxy)-propyl-3-trimethylammonium, o-mysristoyl chitosan enhances the solubility and intestinal permeability of anticancer curcumin
Silva, D
Amphiphilic polymers
Chitosan derivatives
Curcumin
Intestinal delivery
Polymeric micelles
Quaternization
title_short N-(2-hydroxy)-propyl-3-trimethylammonium, o-mysristoyl chitosan enhances the solubility and intestinal permeability of anticancer curcumin
title_full N-(2-hydroxy)-propyl-3-trimethylammonium, o-mysristoyl chitosan enhances the solubility and intestinal permeability of anticancer curcumin
title_fullStr N-(2-hydroxy)-propyl-3-trimethylammonium, o-mysristoyl chitosan enhances the solubility and intestinal permeability of anticancer curcumin
title_full_unstemmed N-(2-hydroxy)-propyl-3-trimethylammonium, o-mysristoyl chitosan enhances the solubility and intestinal permeability of anticancer curcumin
title_sort N-(2-hydroxy)-propyl-3-trimethylammonium, o-mysristoyl chitosan enhances the solubility and intestinal permeability of anticancer curcumin
author Silva, D
author_facet Silva, D
Santos, D
Almeida, A
Marchiori, L
Campana-Filho, SP
Ribeiro, S
Sarmento, B
author_role author
author2 Santos, D
Almeida, A
Marchiori, L
Campana-Filho, SP
Ribeiro, S
Sarmento, B
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Silva, D
Santos, D
Almeida, A
Marchiori, L
Campana-Filho, SP
Ribeiro, S
Sarmento, B
dc.subject.por.fl_str_mv Amphiphilic polymers
Chitosan derivatives
Curcumin
Intestinal delivery
Polymeric micelles
Quaternization
topic Amphiphilic polymers
Chitosan derivatives
Curcumin
Intestinal delivery
Polymeric micelles
Quaternization
description An amphiphilic derivative of chitosan containing quaternary ammonium and myristoyl groups, herein named as ammonium myristoyl chitosan (DMCat), was synthesized by reacting glycidyltrimethylammonium chloride (GTMAC) and myristoyl chitosan (DMCh). The success of the modification was confirmed using Fourier-transform infrared spectroscopy (FTIR) and 1 H nuclear magnetic resonance (NMR) spectroscopy. The average degrees of alkylation and quaternization (DQ) were determined by using 1 H NMR and conductometric titration. The zeta potential of the micelles was higher than 28 mV while its average size and encapsulation efficiency ranged from 280 nm to 375 nm and 68% to 100%, respectively. The in vitro cytotoxicity of the unloaded and curcumin (CUR)-loaded micelles was tested against Caco-2 and HT29-MTX intestinal epithelial cell lines. The results showed no cytotoxic effect from loaded and unloaded micelles as compared to free CUR. In the permeability test, it was observed that both types of micelles, i.e., DMCh and DMCat, improved CUR permeability. Additionally, higher permeability was verified for both systems in Caco-2/HT29-MTX:Raji B because of the mucoadhesive character of chitosan and its ability to open tight junctions. The results indicated that DMCat micelles, due to the physico-chemical, improved characteristics may be a promising carrier to encapsulate CUR aiming cancer therapy.
publishDate 2018
dc.date.none.fl_str_mv 2018
2018-01-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://hdl.handle.net/10216/127428
url https://hdl.handle.net/10216/127428
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 1999-4923
10.3390/pharmaceutics10040245
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799135627018502144